<PAGE>
---------------------------
OMB APPROVAL
---------------------------
OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response....14.90
---------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4 )*
---------
Copley Pharmaceutical, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
21745K-10-1
--------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 9 pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 21745K-10-1 13G PAGE 2 OF 9 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Jane C.I. Hirsh
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
USA
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
1,412,677
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
1,412,677
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,412,677
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [_]
10
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
7.34%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 9 pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 21745K-10-1 13G PAGE 3 OF 9 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mark Hirsh
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
USA
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
1,412,677
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
1,412,677
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,412,677
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [_]
10
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
7.34%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 3 of 9 pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 21745K-10-1 13G PAGE 4 OF 9 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Theodore L. Iorio
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
USA
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 309,087
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
1,287,495
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 309,087
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
1,287,495
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,596,582
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [_]
10
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
8.30%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 4 of 9 pages
<PAGE>
Item 1(a). Name of Issuer: Copley Pharmaceutical, Inc.
--------------
Item 1(b). Address of Issuer's Principal Executive Offices:
-----------------------------------------------
25 John Road, Canton, MA 02021
Item 2(a). Name of Person Filing: Jane C.I. Hirsh, Mark Hirsh and Theodore L.
---------------------
Iorio (the "Reporting Persons").
Item 2(b). Address of Principal Business Office or, if None, Residence: The
-----------------------------------------------------------
principal business office of each of the Reporting Persons is c/o
Copley Pharmaceutical, Inc., 25 John Road, Canton, MA 02021.
Item 2(c). Citizenship: Jane C.I. Hirsh, Mark Hirsh and Theodore L. Iorio are
-----------
United States citizens.
Item 2(d). Title of Class of Securities: Common Stock, $.01 par value per
----------------------------
share ("Common Stock").
Item 2(e). CUSIP Number: 21745K-10-1.
------------
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b),
-------------------------------------------------------------------
check whether the person filing is a:
------------------------------------
(a) [ ] Broker or Dealer registered under Section 15 of the
Securities Exchange Act of 1934 (the "Act").
(b) [ ] Bank as defined in Section 3(a)(6) of the Act.
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the
Act.
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940.
(e) [ ] Investment Advisor registered under Section 203 of the
Investment Advisers Act of 1940.
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security Act of
1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F) of the Act.
(g) [ ] Parent Holding Company, in accordance with Rule 13d-
1(b)(ii)(G) of the Act.
(h) [ ] Group, in accordance with Rule 13a-1(b)(1)(ii)(H) of the
Act.
<PAGE>
Item 4. Ownership.
---------
(a) Amount Beneficially Owned:
Jane C.I. Hirsh is the record owner of 112,500 shares (which number
includes 112,500 options exercisable within 60 days of 12/31/96). Ms.
Hirsh may be deemed to beneficially own 24,429 shares and 6,889 shares
which are allocated to herself and her spouse, Mark Hirsh,
respectively, in the Copley Pharmaceutical, Inc. Employee Stock
Ownership Plan. By virtue of her status as the spouse of Mark Hirsh,
Ms. Hirsh may be deemed to beneficially own 45,000 shares of Common
Stock which are individually owned by Mark Hirsh (which number
includes 45,000 options exercisable within 60 days of 12/31/96) and
133,763 shares which Mark Hirsh owns in his capacity as the general
partner of Romeo Partners. By virtue of her status as a trustee of The
Hirsh Family Foundation, Ms. Hirsh may be deemed to beneficially own
29,718 shares which are held by The Hirsh Family Foundation. Ms. Hirsh
may be deemed to beneficially own 860,378 shares by virtue of her
status as the general partner of Juliet Partners. Ms. Hirsh may be
deemed to beneficially own 200,000 shares by virtue of her status as a
general partner in NMJ Limited Partnership. Therefore, Ms. Hirsh may
be deemed to be the beneficial owner of 1,412,677 shares of Common
Stock. Ms. Hirsh expressly disclaims beneficial ownership of shares of
Common Stock held of record by The Hirsh Family Foundation, Mark Hirsh
and/or allocated in the Copley Pharmaceutical, Inc. Employee Stock
Ownership Plan to Mark Hirsh.
Mark Hirsh is the record owner of 45,000 shares (which number includes
45,000 options exercisable within 60 days of 12/31/96). Dr. Hirsh may
be deemed to beneficially own 24,429 shares and 6,889 shares which are
allocated to his spouse, Jane C.I. Hirsh, and himself, respectively,
in the Copley Pharmaceutical, Inc. Employee Stock Ownership Plan. By
virtue of his status as the spouse of Jane C.I. Hirsh, Dr. Hirsh may
be deemed to beneficially own 112,500 shares of Common Stock which are
individually owned by Jane C.I. Hirsh (which number includes 112,500
options exercisable within 60 days of 12/31/96) and 860,378 which Jane
Hirsh owns in her capacity as the general partner of Juliet Partners.
By virtue of his status as a trustee of The Hirsh Family Foundation,
Dr. Hirsh may be deemed to beneficially own 29,718 shares which are
held by The Hirsh Family Foundation. Dr. Hirsh may be deemed to
beneficially own 133,763 shares by virtue of his status as the general
partner of Romeo Partners. Mr. Hirsch may be deemed to beneficially
own 200,000 shares by virtue of his status as a general partner in NMJ
Limited Partnership. Therefore, Dr. Hirsh may be deemed to be the
beneficial owner of 1,412,677 shares of Common Stock. Dr. Hirsh
expressly disclaims beneficial ownership of shares of Common Stock
held of record by The Hirsh Family Foundation, Jane C.I. Hirsh and/or
allocated in the Copley Pharmaceutical, Inc. Employee Stock Ownership
Plan to Jane C.I. Hirsh.
Theodore L. Iorio is the record owner of 286,885 shares (which number
includes 150,605 options exercisable within 60 days of 12/31/96).
Additionally, Mr. Iorio may be deemed to beneficially own: 36,654
shares which are held of record by the Iorio Family Foundation;
163,932 shares which are held of record by the Theodore L. Iorio
Charitable Remainder Trust; 653,454 shares which are held of record by
the Theodore L. Iorio Standard Trust; and 22,202 shares allocated to
Mr. Iorio in the Copley Pharmaceutical, Inc. Employee Stock Ownership
Plan. Also includes 433,455 shares held by trusts for the benefit of
certain members of Mr. Iorio's family, for which Mr. Iorio's spouse is
custodian, the beneficial ownership of which Mr. Iorio disclaims.
Therefore, Mr. Iorio may be deemed to be the beneficial owner of
1,596,582 shares of Common Stock. Mr. Iorio expressly disclaims
beneficial ownership of shares of Common Stock held of record by the
Iorio Family Foundation and the Theodore L. Iorio Charitable Remainder
Trust.
(b) Percent of Class:
Jane C.I. Hirsh, Mark Hirsh, and Theodore L. Iorio may be deemed to
beneficially own 7.34%, 7.34%, and 8.30%, respectively (based on the
19,088,579 shares of Common Stock reported to be outstanding on
October 31, 1996 in the Copley Pharmaceutical, Inc. Quarterly Report
on Form 10-Q for the fiscal quarter ended 9/30/96).
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
Jane C.I. Hirsh: 0
Hark Hirsh 0
Theodore L. Iorio 309,087
(ii) shared power to vote or to direct the vote:
Page 6 of 9 pages
<PAGE>
Jane C.I. Hirsh: 1,412,677
Mark Hirsh 1,412,677
Theodore L. Iorio 1,287,495
(iii) sole power to dispose or to direct the disposition of:
Jane C.I. Hirsh: 0
Mark Hirsh 0
Theodore L. Iorio 309,087
(iv) shared power to dispose or to direct the disposition of:
Jane C.I. Hirsh: 1,412,677
Mark Hirsh 1,412,677
Theodore L. Iorio 1,287,495
Item 5. Ownership of Five Percent or Less of a Class.
--------------------------------------------
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the
following [ ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
---------------------------------------------------------------
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
----------------------------------------------------------------------
Security Being Reported on by the Parent Holding Company.
--------------------------------------------------------
Not applicable. This statement is not filed pursuant to Rule 13d-
1(b)(ii)(G).
Item 8. Identification and Classification of Members of the Group.
---------------------------------------------------------
Not applicable. This statement is not filed pursuant to Rule 13d-
1(b)(ii)(H).
Item 9. Notice of Dissolution of Group.
------------------------------
Not applicable.
Item 10. Certification.
-------------
Not applicable. This statement is not filed pursuant to Rule 13d-
1(b).
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Page 7 of 9 pages
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February __, 1997 _______________________________________
Jane C.I. Hirsh
_______________________________________
Mark Hirsh
_______________________________________
Theodore L. Iorio
Page 8 of 9 pages
<PAGE>
EXHIBIT I
---------
Pursuant to Rule 13d-1(f)(1) under the Securities Exchange Act of 1934, the
undersigned hereby agree that only one statement containing the information
required on Amendment No. 4 to Schedule 13G need be filed with respect to
ownership by each of the undersigned of shares of Common Stock of Copley
Pharmaceutical, Inc.
This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original.
Dated: February __, 1997 _______________________________________
Jane C.I. Hirsh
_______________________________________
Mark Hirsh
_______________________________________
Theodore L. Iorio
Page 9 of 9 pages
